Article:

# ACCELERATING THE NEXT GENERATION OF URINARY TRACT INFECTION (UTI) TREATMENTS IN WOMEN

## Clinical and Regulatory Considerations for Advancing Women's Health Drug Development

*Featuring the Medpace Women's Health Leadership Team, Aparna Shah, MD, FACOG, Medical Director, Women's Health, Medpace, Rujin Ju, MD, MSCR, FACOG, Medical Director, Women's Health, Medpace, and Beth Tulip, Senior Executive Director, Clinical Trial Management, Women's Health & Infectious Diseases, Medpace*

## THE EVOLVING LANDSCAPE OF UTI DRUG DEVELOPMENT

Urinary tract infections (UTIs) remain a persistent clinical challenge and a significant burden on global healthcare systems, disproportionately impacting women across their lifespan. With the rise of antimicrobial resistance (AMR), an aging and vulnerable patient population, and a growing emphasis on patient-centered innovation, the clinical development of novel UTI therapies is approaching a critical inflection point.

Historically underrepresented in drug development pipelines, UTIs now represent a significant opportunity for biopharmaceutical companies to address an area of high unmet need in women's health. In this article, Medpace's Women's Health and Infectious Disease experts explore the compound challenges and opportunities shaping the next generation of UTI drug development. From clinical complexities to regulatory evolution, we outline key considerations to accelerate innovation and improve outcomes for women across the globe.

## UNDERSTANDING THE BURDEN – WHY UTI DRUG DEVELOPMENT DEMANDS INNOVATION

UTIs are among the most common infectious diseases worldwide, affecting 50-60% of adult women at least once in their lifetime.[1] Despite their prevalence and clinical impact, UTIs remain underrepresented in research, particularly in the context of women's health research and drug development. Recurrent UTIs (rUTIs) affect up to 30% of women, often leading to frequent antibiotic use, diminished quality of life, and increased healthcare costs.[2] Postmenopausal women represent a particularly vulnerable population due to hormonal and anatomical changes, with approximately 10% reporting a UTI each year.[3]

The rising presence of multi-drug-resistant (MDR) uropathogens, such as *E. coli* and *K. pneumoniae*, is further compounding the challenge, reducing the effectiveness of traditional first-line therapies.[4] The convergence of recurrence and resistance underscores the urgent need for an innovative approach to UTI clinical development.

## CLINICAL COMPLEXITIES IN UTI DRUG DEVELOPMENT

### *Overcoming Antibiotic Resistance: A Shifting Treatment Paradigm*

Antibiotic resistance is reshaping the therapeutic landscape for UTIs. The increasing prevalence of MDR uropathogens necessitates the exploration of alternatives to conventional antimicrobials. These include antibiotics with novel mechanisms of action, non-antibiotic therapies (including immunotherapies, bacteriophage therapy, and probiotics), and vaccines and microbiome-modulating interventions.[5]

Regulatory agencies including the FDA and EMA are increasingly receptive to these emerging approaches, offering flexibility through adaptive trial designs and novel endpoints—provided they reflect clinically meaningful benefit.

### *Distinct Pathways: Uncomplicated vs. Recurrent Infections*

Designing effective clinical trials for UTI therapies begins with defining patient populations. A key clinical complexity lies in the distinction between uncomplicated UTIs (uUTIs) and recurrent UTIs (rUTIs). uUTIs typically occur in healthy women without anatomical or functional abnormalities, whereas rUTIs involve repeated infections within a defined period and are influenced by multiple risk factors or comorbidities. These distinctions demand different clinical approaches, trial endpoints, and regulatory considerations.[6] For example, in depth understanding of the nuances of rUTI as compared to uUTI is required in site selection; while optimal sites for uUTI studies may range from primary care practices to general obstetric and gynecologic practices, optimal sites for rUTI may also include specialty practices including infectious disease, urogynecology, and urology practices.

### *Evolving Expectations Around Clinical Endpoints*

Traditional UTI trials have heavily relied on microbiological eradication as a primary endpoint. While pathogen clearance remains an important benchmark, it does not always reflect the full therapeutic impact—particularly from the patient's perspective. As the regulatory landscape shifts, there is an increasing emphasis on endpoints that reflect meaningful symptom relief and patient-reported outcomes. In line with this shift, U.S. Food and Drug Administration guidance recommends that "the primary efficacy endpoint should be based on a responder outcome of clinical and microbiologic response," reflecting the importance of assessing not only laboratory evidence of cure but also patient symptoms and clinical response.[7]

## STRATEGIC CONSIDERATIONS FOR OPTIMIZING UTI CLINICAL TRIALS

Successfully advancing UTI therapies requires thoughtful planning across clinical, operational, and regulatory domains. As the landscape adapts, biopharmaceutical companies must take a proactive approach to trial design, endpoint selection, regulatory alignment, and patient engagement.

### *Defining the Right Patient Cohort*

Robust study design begins with well-defined patient populations. Differentiating between uncomplicated (uUTIs) and recurrent (rUTI) infections is critical, as these subtypes involve distinct clinical profiles, risk factors, and treatment considerations. For example, rUTIs—commonly defined by multiple symptomatic episodes within a six- to twelve-month period—often require longer study durations, tracking of prior antibiotic use, and stratification based on recurrence history.

Strategic inclusion and exclusion criteria can improve both scientific rigor and generalizability. Trials should account for diverse patient groups, including postmenopausal women and those with comorbidities or prior treatment failures. These subgroups are frequently underrepresented yet highly relevant to real-world treatment patterns. Carefully structured eligibility parameters can help balance internal validity with external applicability, strengthening both the regulatory and clinical impact of trial outcomes.

### *Selecting Clinically Meaningful Endpoints*

Endpoints are increasingly being reframed to capture real-world evidence. While microbiological eradication has historically been a regulatory standard, it does not always reflect the patient-perceived benefit or sustained therapeutic effect. Biopharmaceutical companies are adopting more holistic approaches—including symptom resolution, time to improvement, recurrence rates, and sustained clinical response—to better reflect efficacy from both a clinical and patient perspective.

Incorporating patient-reported outcomes (PROs) and quality of life (QoL) measures is especially valuable in recurrent UTI studies, where the impact on daily functioning and well-being can be substantial. Regulatory authorities such as the FDA and EMA are encouraging the adoption of endpoints that move beyond laboratory markers to more accurately reflect meaningful clinical outcomes.

### *Embedding Clinical and Operational Expertise*

Successful trial execution requires the integration of scientific leadership across the project lifecycle. Embedding therapeutic experts from protocol development through study closeout ensures that scientific objectives are maintained without compromising operational feasibility. Medical oversight throughout the trial supports continuity in decision-making, better protocol adherence, and more responsive issue management.

Cross-functional collaboration, particularly between women's health and infectious disease specialists, enables integrated planning and problem-solving. It also promotes adaptive strategies to address challenges such as antimicrobial resistance (AMR), patient variability, and evolving regulatory expectations.

### *Navigating Regulatory Pathways and Aligning with Global Expectations*

The growing impact of antimicrobial resistance has prompted regulatory bodies to refine guidance for UTI drug development, accelerating development pathways and trial designs. Still, biopharma must be prepared to navigate the complex distinctions between uUTI and rUTI regulatory requirements. Early engagement with regulators—ideally during protocol development—can ensure alignment on key parameters including endpoints, population definitions, and statistical approaches.

Close collaboration with investigators and key opinion leaders (KOLs) can also inform study strategy and enhance credibility with regulators. Leveraging input from both regulators and clinicians ensures trial design is grounded in scientific best practices and aligned with evolving regional standards.

### *Improving Patient Recruitment & Retention*

Patient recruitment remains one of the most significant challenges in UTI clinical development, particularly in trials involving recurrent or long-duration treatment. Sponsors should prioritize strategies that improve inclusivity—such as targeting postmenopausal populations—and expand beyond traditional sites to boost enrollment efficacy.

Retention is equally critical, especially in longer-term studies that track recurrence over time. Clear communication, site engagement, and patient-centric protocol designs, including flexible visit schedules and simplified data collection, can improve adherence and data completion.

### *A Precision Approach: Novel Biomarkers & Personalized Medicine*

UTI clinical development is beginning to embrace the promise of precision medicine. Emerging technologies such as predictive biomarkers, rapid diagnostics, and microbiome profiling can improve patient selection and stratification while enabling real-time trial adaptations.[8,9] Emerging research in genomics and immunomodulation strategies is also creating new opportunities for targeting specific patient subgroups and enhancing therapeutic outcomes.[10] These approaches offer notable potential to personalize UTI treatment and redefine clinical success.

## YOUR NEXT BREAKTHROUGH STARTS HERE

### *A Full-Service Approach to UTI Clinical Development*

Bringing the next generation of UTI therapies to market requires a partner with scientific depth, regulatory insight, and operational scale. Medpace brings a full-service, integrated approach to UTI clinical development, combining regulatory insight, scientific rigor, and global executional strength.

Our cross-functional Women's Health Leadership Team draws on decades of experience in infectious diseases, vaccines, and women's health research—ensuring that study designs are both scientifically sound and operationally feasible. With strong relationships across key opinion leaders (KOLs), regulatory agencies, global investigators, and specialized laboratories, Medpace provides biopharmaceutical companies with a connected network that supports every phase of the trial lifecycle.

Our integrated model enables greater alignment, faster execution, and more meaningful outcomes—empowering Sponsors to bring innovative UTI treatments to patients faster.

Your next breakthrough in women's health starts here—connect with our Women's Health Leadership Team today.

## REFERENCES


1. Medina, M., & Castillo-Pino, E. (2019). An introduction to the epidemiology and burden of urinary tract infections. *Therapeutic advances in urology*, *11*, 1756287219832172. https://doi.org/10.1177/1756287219832172

2. Eells, S. J., Bharadwa, K., McKinnell, J. A., & Miller, L. G. (2014). Recurrent urinary tract infections among women: comparative effectiveness of 5 prevention and management strategies using a Markov chain Monte Carlo model. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*, 58(2), 147–160. https://doi.org/10.1093/cid/cit646

3. Medina, M., & Castillo-Pino, E. (2019). An introduction to the epidemiology and burden of urinary tract infections. *Therapeutic advances in urology*, *11*, 1756287219832172. https://doi.org/10.1177/1756287219832172

4. Rozwadowski, M., & Gawel, D. (2022). Molecular Factors and Mechanisms Driving Multidrug Resistance in Uropathogenic *Escherichia coli*-An Update. *Genes*, 13(8), 1397. https://doi.org/10.3390/genes13081397

5. Loubet, P., Ranfaing, J., Dinh, A., Dunyach-Remy, C., Bernard, L., Bruyère, F., Lavigne, J. P., & Sotto, A. (2020). Alternative Therapeutic Options to Antibiotics for the Treatment of Urinary Tract Infections. *Frontiers in microbiology*, *11*, 1509. https://doi.org/10.3389/fmicb.2020.01509

6. Aggarwal N, Leslie SW. Recurrent Urinary Tract Infections. [Updated 2025 Jan 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557479/

7. U.S. Food and Drug Administration. (2020). *Uncomplicated Urinary Tract Infections: Developing Drugs for Treatment*. Retrieved from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/uncomplicated-urinary-tract-infections-developing-drugs-treatment-guidance-industry

8. Maddah, R., Ghanbari, F., Veisi, M., Koosehlar, E., Shadpirouz, M., Basharat, Z., Hejrati, A., Amiri, B. S., & Hejrati, L. (2024). Unveiling Potential Biomarkers for Urinary Tract Infection: An Integrated Bioinformatics Approach. *Advanced biomedical research*, *13*, 44. https://doi.org/10.4103/abr.abr_355_23

9. Davenport, M., Mach, K. E., Shortliffe, L. M. D., Banaei, N., Wang, T. H., & Liao, J. C. (2017). New and developing diagnostic technologies for urinary tract infections. *Nature reviews. Urology*, *14*(5), 296–310. https://doi.org/10.1038/nrurol.2017.20

10. Kim, D. S., & Lee, J. W. (2023). Urinary Tract Infection and Microbiome. *Diagnostics (Basel, Switzerland)*, *13*(11), 1921. https://doi.org/10.3390/diagnostics13111921